×

Raptor Pharmaceutical to Present at Upcoming Investor Conference

company logo

NOVATO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, Raptor's Executive Vice President, Strategy and Chief Operating Officer, will present an overview of the company at the Canaccord Genuity 33rd Annual Growth Conference in Boston. Raptor's presentation will take place on Thursday, August 15, 2013 beginning at 9:30 a.m. EDT/6:30 a.m. PDT.

A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company's first product, PROCYSBI® (cysteamine bitartrate) delayed-release capsules, has been approved by the FDA, and recommended for marketing authorization by the European Committee for Medicinal Products for Human Use (CHMP) for the management of nephropathic cystinosis, a rare metabolic lysosomal storage disease. Raptor's pipeline also includes RP103 in a Phase 2/3 trial for Huntington's disease and a Phase 2 trial in nonalcoholic fatty liver disease in children. PROCYSBI has orphan designation for nephropathic cystinosis in the U.S. and recommended designation in the EU and RP103 has received U.S. orphan drug designation for Huntington's disease. For additional information, please visit www.raptorpharma.com.

CONTACT: Georgia Erbez Chief Financial Officer Raptor Pharmaceutical Corp. (415) 408-6231 gerbez@raptorpharma.com INVESTOR CONTACTS: Westwicke Partners, LLC Stefan Loren, Ph.D. Managing Director (443) 213-0507 sloren@westwicke.com Robert H. Uhl Managing Director (858) 356-5932 robert.uhl@westwicke.com MEDIA CONTACT: Carolyn Hawley Canale Communications (619) 849-5375 carolyn@canalecomm.com

Source:Raptor Pharmaceutical Corp.

More From Press Releases